Torbjørn Wisløff

Norwegian Institute of Public Health

 

Original articles

Haugnes H, Elstrøm P, Kacelnik O, Jadczak U, Wisløff T, de Blasio BF (2019)
Financial and temporal costs of patient isolation in Norwegian hospitals
J Hosp Infect (in press)
DOI 10.1016/j.jhin.2019.11.012, PubMed 31760129

Jelin E, Wisløff T, Jørstad ØK, Heiberg T, Moe MC (2019)
Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study
BMJ Open Ophthalmol, 4 (1), e000353
DOI 10.1136/bmjophth-2019-000353, PubMed 31673632

Jelin E, Wisløff T, Moe MC, Heiberg T (2019)
Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) in a Norwegian population of patients with neovascular age-related macular degeneration compared to a control population
Health Qual Life Outcomes, 17 (1), 140
DOI 10.1186/s12955-019-1203-0, PubMed 31412873

Wisløff T, Mundal LJ, Retterstøl K, Igland J, Kristiansen IS (2019)
Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects
Atherosclerosis, 287, 140-146
DOI 10.1016/j.atherosclerosis.2019.06.900, PubMed 31280039

Haugnes H, Flem E, Wisløff T (2019)
Healthcare costs associated with varicella and herpes zoster in Norway
Vaccine, 37 (29), 3779-3784
DOI 10.1016/j.vaccine.2019.05.063, PubMed 31151798

Evensen S, Wisløff T, Lystad JU, Bull H, Martinsen EW, Ueland T, Falkum E (2019)
Exploring the potential cost-effectiveness of a vocational rehabilitation program for individuals with schizophrenia in a high-income welfare society
BMC Psychiatry, 19 (1), 140
DOI 10.1186/s12888-019-2130-7, PubMed 31064371

Gjerset GM, Kiserud CE, Loge JH, Fosså SD, Wisløff T, Gudbergsson SB, Oldervoll LM, Thorsen L (2019)
Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors
Acta Oncol, 58 (5), 682-689
DOI 10.1080/0284186X.2018.1562210, PubMed 30862228

Bøhn SH, Thorsen L, Kiserud CE, Fosså SD, Lie HC, Loge JH, Wisløff T, Haugnes HS, Reinertsen KV (2019)
Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood
Acta Oncol, 58 (5), 753-762
DOI 10.1080/0284186X.2018.1557344, PubMed 30696351

Sahba M, Krog AH, Pettersen EM, Wisloff T, Rogne KG, Sundhagen JO, Kazmi SSH (2019)
Cost comparison analysis of laparoscopic versus open aortobifemoral bypass surgery: a randomized controlled trial
Open Access J. Clin. Trials, 11, 11-18

Andreasen C, Solberg LB, Basso T, Borgen TT, Dahl C, Wisløff T, Hagen G, Apalset EM, Gjertsen JE, Figved W, Hübschle LM, Stutzer JM, Elvenes J, Joakimsen RM, Syversen U, Eriksen EF, Nordsletten L, Frihagen F, Omsland TK, Bjørnerem Å (2018)
Effect of a Fracture Liaison Service on the Rate of Subsequent Fracture Among Patients With a Fragility Fracture in the Norwegian Capture the Fracture Initiative (NoFRACT): A Trial Protocol
JAMA Netw Open, 1 (8), e185701
DOI 10.1001/jamanetworkopen.2018.5701, PubMed 30646281

Lousdal ML, Møller MH, Kristiansen IS, Kalager M, Wisløff T, Støvring H (2018)
The Screening Illustrator: separating the effects of lead-time and overdiagnosis in mammography screening
Eur J Public Health, 28 (6), 1138-1142
DOI 10.1093/eurpub/cky085, PubMed 29796623

Jelin E, Wisløff T, Moe MC, Heiberg T (2018)
Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration
Acta Ophthalmol, 96 (8), 804-811
DOI 10.1111/aos.13847, PubMed 30198182

Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T (2018)
Are PCSK9 Inhibitors Cost Effective?
Pharmacoeconomics, 36 (9), 1031-1041
DOI 10.1007/s40273-018-0671-0, PubMed 29777433

Bøhn SH, Fosså SD, Wisløff T, Thorsen L (2018)
Physical activity and associations with treatment-induced adverse effects among prostate cancer patients
Support Care Cancer, 27 (3), 1001-1011
DOI 10.1007/s00520-018-4389-5, PubMed 30094728

Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Kløvstad H (2018)
Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies
J Viral Hepat, 25 (9), 1066-1077
DOI 10.1111/jvh.12904, PubMed 29624813

Bleka Ø, Wisløff T, Dahlberg PS, Rolseth V, Egeland T (2018)
Advancing estimation of chronological age by utilizing available evidence based on two radiographical methods
Int J Legal Med, 133 (1), 217-229
DOI 10.1007/s00414-018-1848-y, PubMed 29736772

Wisløff T, White R, Dalgard O, Amundsen EJ, Meijerink H, Løvlie AL, Kløvstad H (2018)
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
Pharmacoeconomics, 36 (5), 591-601
DOI 10.1007/s40273-017-0604-3, PubMed 29396744

Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM, Wisloff T, Kristiansen IS, Tell GS, Leren TP, Retterstøl K (2018)
Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
Heart, 104 (19), 1600-1607
DOI 10.1136/heartjnl-2017-312706, PubMed 29622598

Korman M, Wisløff T (2018)
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
Eur Heart J Cardiovasc Pharmacother, 4 (1), 15-22
DOI 10.1093/ehjcvp/pvx010, PubMed 28444187

Krog AH, Sahba M, Pettersen EM, Wisløff T, Sundhagen JO, Kazmi SS (2017)
Cost-utility analysis comparing laparoscopic vs open aortobifemoral bypass surgery
Vasc Health Risk Manag, 13, 217-224
DOI 10.2147/VHRM.S138516, PubMed 28670132

Lie I, Danielsen SO, Tønnessen T, Solheim S, Leegaard M, Sandvik L, Wisløff T, Vangen J, Røsstad TH, Moons P (2017)
Determining the impact of 24/7 phone support on hospital readmissions after aortic valve replacement surgery (the AVRre study): study protocol for a randomised controlled trial
Trials, 18 (1), 246
DOI 10.1186/s13063-017-1971-y, PubMed 28693599

Gjerset GM, Loge JH, Kiserud CE, Fosså SD, Gudbergsson SB, Oldervoll LM, Wisløff T, Thorsen L (2017)
Perceived needs for different components in a rehabilitation program among cancer survivors with chronic fatigue compared to survivors without chronic fatigue
Acta Oncol, 56 (2), 245-253
DOI 10.1080/0284186X.2016.1266091, PubMed 28075207

Pike E, Hamidi V, Ringerike T, Wisloff T, Klemp M (2016)
More Use of Peritoneal Dialysis Gives Significant Savings: A Systematic Review and Health Economic Decision Model
J Clin Med Res, 9 (2), 104-116
DOI 10.14740/jocmr2817w, PubMed 28090226

Werner EL, Storheim K, Løchting I, Wisløff T, Grotle M (2016)
Cognitive Patient Education for Low Back Pain in Primary Care: A Cluster Randomized Controlled Trial and Cost-Effectiveness Analysis
Spine (Phila Pa 1976), 41 (6), 455-62
DOI 10.1097/BRS.0000000000001268, PubMed 26966970

Hagen G, Wisløff T, Kristiansen IS (2016)
The predicted lifetime costs and health consequences of calcium and vitamin D supplementation for fracture prevention-the impact of cardiovascular effects
Osteoporos Int, 27 (6), 2089-98
DOI 10.1007/s00198-016-3495-9, PubMed 26846776

Meyer K, Wahl AK, Bjørk IT, Wisløff T, Hartmann A, Andersen MH (2016)
Long-term, self-reported health outcomes in kidney donors
BMC Nephrol, 17, 8
DOI 10.1186/s12882-016-0221-y, PubMed 26754798

Wisløff T, Atar D (2016)
Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
Eur Heart J Qual Care Clin Outcomes, 2 (1), 52-57
DOI 10.1093/ehjqcco/qcv023, PubMed 29474586

Evensen S, Wisløff T, Lystad JU, Bull H, Ueland T, Falkum E (2015)
Prevalence, Employment Rate, and Cost of Schizophrenia in a High-Income Welfare Society: A Population-Based Study Using Comprehensive Health and Welfare Registers
Schizophr Bull, 42 (2), 476-83
DOI 10.1093/schbul/sbv141, PubMed 26433216

Wisløff T, Hagen G, Klemp M (2014)
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation
Pharmacoeconomics, 32 (6), 601-12
DOI 10.1007/s40273-014-0152-z, PubMed 24715603

Wisløff T, Atar D, Sønbø Kristiansen I (2013)
Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease
Am J Ther, 20 (6), 596-601
DOI 10.1097/MJT.0b013e3182211a01, PubMed 21822114

Boberg KM, Wisløff T, Kjøllesdal KS, Støvring H, Kristiansen IS (2013)
Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid
Aliment Pharmacol Ther, 38 (7), 794-803
DOI 10.1111/apt.12435, PubMed 23915021

Støvring H, Harmsen CG, Wisløff T, Jarbøl DE, Nexøe J, Nielsen JB, Kristiansen IS (2012)
A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality
Eur J Prev Cardiol, 20 (5), 827-36
DOI 10.1177/2047487312445425, PubMed 22498473

Wisløff T, Selmer RM, Halvorsen S, Fretheim A, Norheim OF, Kristiansen IS (2012)
Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis
BMC Cardiovasc Disord, 12, 26
DOI 10.1186/1471-2261-12-26, PubMed 22475076

Wisløff T, Aalen OO, Kristiansen IS (2010)
Considerable variation in NNT - a study based on Monte Carlo simulations
J Clin Epidemiol, 64 (4), 444-50
DOI 10.1016/j.jclinepi.2010.04.025, PubMed 20947294

Berntsen S, Wisløff T, Nafstad P, Nystad W (2008)
Lung function increases with increasing level of physical activity in school children
Pediatr Exerc Sci, 20 (4), 402-10
DOI 10.1123/pes.20.4.402, PubMed 19168917

Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U (2008)
Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden
Scand J Infect Dis, 40 (9), 721-9
DOI 10.1080/00365540802014872, PubMed 18712627

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Kristiansen IS (2006)
[Vaccination--value for money?]
Tidsskr Nor Laegeforen, 126 (20), 2670-3
PubMed 17057767

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS (2006)
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program
Vaccine, 24 (29-30), 5690-9
DOI 10.1016/j.vaccine.2006.04.042, PubMed 16735083

Norderhaug IN, Wisløff T, Fosså S, Sandberg S, Malde K, Forland F, Førde OH (2004)
[Dissemination of evidence-based information about PSA test and prostatic cancer to physicians]
Tidsskr Nor Laegeforen, 124 (22), 2893-5
PubMed 15550959

Wisløff T, Halvorsen PA, Kristiansen IS (2004)
[Number needed to treat (NNT)-- misleading, misunderstood, misused?]
Tidsskr Nor Laegeforen, 124 (15), 1926-9
PubMed 15306861

Nafstad P, Håheim LL, Wisløff T, Gram F, Oftedal B, Holme I, Hjermann I, Leren P (2004)
Urban air pollution and mortality in a cohort of Norwegian men
Environ Health Perspect, 112 (5), 610-5
DOI 10.1289/ehp.6684, PubMed 15064169

Review articles

Wisløff T, Hagen G, Hamidi V, Movik E, Klemp M, Olsen JA (2014)
Estimating QALY gains in applied studies: a review of cost-utility analyses published in 2010
Pharmacoeconomics, 32 (4), 367-75
DOI 10.1007/s40273-014-0136-z, PubMed 24477679

Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M (2012)
Cancer risk with folic acid supplements: a systematic review and meta-analysis
BMJ Open, 2 (1), e000653
DOI 10.1136/bmjopen-2011-000653, PubMed 22240654

Bell RF, Wisløff T, Eccleston C, Kalso E (2006)
Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review
Br J Cancer, 94 (11), 1559-67
DOI 10.1038/sj.bjc.6603162, PubMed 16705312

Other articles

Wisløff T (2017)
[New Norwegian threshold value for a good year of life?]
Tidsskr Nor Laegeforen, 137 (7), 518
DOI 10.4045/tidsskr.17.0137, PubMed 28383223

Wisloff T, Robberstad B (2015)
Markov - modeling
Tidsskr. Nor. Laegeforen., 135 (16), 1432

Wisløff T, Robberstad B (2015)
[Re: Markov modeling]
Tidsskr Nor Laegeforen, 135 (16), 1432
DOI 10.4045/tidsskr.15.0837, PubMed 26356444

Wisløff T (2015)
Priority-setting criteria in the Norwegian health services
Tidsskr Nor Laegeforen, 135 (15), 1373-5
DOI 10.4045/tidsskr.15.0228, PubMed 26315241

Wisloff T, Aalen OO, Kristiansen IS (2012)
Regarding adequate methods for comparison of effect measures reply
J. Clin. Epidemiol., 65 (4), 462-463

Norheim OF, Gjelsvik B, Klemsdal TO, Madsen S, Meland E, Narvesen S, Negard A, Njolstad I, Tonstad S, Ulvin F, Wisloff T (2011)
Norway's new principles for primary prevention of cardiovascular disease: age differentiated risk thresholds
BMJ-British Medical Journal, 343, d3626

Books

Kløw NE, Rotevatn S, Steigen T, Vatne K, Wisløff T, Kristensen IS, Norderhaug I (2004)
Forebygging av restenose i hjertets kransårer
In Rapport, Kunnskapssenteret, Oslo, nr 8/2004, 143 s.
BIBSYS 050087517, ISBN 82-8121-008-7

Page visits: 77